HemoCue, Inc. 40 Empire Dr Lake Forest, CA 92630   Phone (800) 323-1674 Fax (800) 333-7043   info@hemocue.com  www.hemocue.com    Online Privacy Policy    Printer-Friendly	HemoCue develops, produces and markets medical diagnostic products for point-of-care testing. The fundamental concept behind HemoCue products is to perform point-of-care tests without sacrificing the precision and accuracy offered by a central lab.   HemoCue, Inc., a subsidiary of HemoCue AB, was founded in the United States in 1989.     In 1974, the two inventors of the HemoCue system, Sven-Erik Nilsson and Jan Lilja started work on the cuvette concept. HemoCue AB was founded in Helsingborg, Sweden in 1982. Our systems are based on reliable cuvette technology, reagent chemistry and analyte-specific instruments. These systems do not require mixing of reagents, dispensing, or pipetting. The instruments are factory calibrated and all cuvettes are produced such that no adjustment for batch-to-batch variation is necessary, and requires minimum training and instrument maintenance. This makes it possible for staff without laboratory training to consistently perform tests yielding accurate results.     The HemoCue Hemoglobin System was introduced in the early 1980s. The HemoCue Glucose System was introduced on a worldwide basis in the beginning of the 1990s, Urine Albumin in 2006, and the White Blood Cell Count in 2008. Since the introduction, we have placed over 250,000 analyzers and photometers globally. HemoCue was acquired by Quest Diagnostics (www.questdiagnostics.com) on February 1st 2007. The HemoCue product line is sold in more than 120 countries through a highly effective organization consisting of independent distributor partners and subsidiaries.   HemoCue is a company that has developed a keen sensitivity for the needs of customers in primary healthcare settings and has a focus on preventive healthcare opportunities. Given current global trends in these areas, our products will continue to provide valuable opportunities on a worldwide basis. For upcoming events, please visit our Corporate Website. HemoCue adheres to a policy of full compliance with the laws and regulations governing its business, not only as a legal obligation, but also because it is the right thing to do.   The Integrity Commitment is the foundation of HemoCue's compliance program. The Integrity Commitment was created to protect and promote the Company?s commitment to compliance.   As a corporate priority, we expect and work to ensure that each of our employees understands and complies with all compliance policies and ethical guidelines. This includes adherence to the Company's Code of Business Ethics (Code). The Code describes the standards of business conduct required of all Focus Diagnostics employees, executive officers and directors. The principles set forth in the Code are supported by the Company's Vision and Values, the Integrity Commitment, the specific and detailed policies and practices contained in Your Compliance Policy Handbook and in other relevant Company policies and procedures. The company provides this framework of principles and procedures to help ensure consistency and alignment between what we say we value and what our actions demonstrate we value.   As a Company, we affirm our ongoing commitment to establishing policies and developing effective internal controls that will promote adherence to our standards of business ethics, our compliance policies and procedures, and the requirements of federal, state and private health care programs, and applicable FDA requirements.   Integrity Commitment  Code of Business Ethics    Please call 1-800-642-4657 ext. 4013 to obtain a hard copy of these documents.